Soon after Fiona Marshall took over the leadership of Novartis Biomedical Research in November 2022, she accelerated the collaboration between the research, development, and commercial organizations of Novartis. In her view, this move is not a renunciation of the company’s basic scientific efforts, but an attempt to create research platforms with high productivity to develop breakthrough medicines for patients around the world.

By Goran Mijuk
Published on 11/09/2024